dr. chau on checkmate577 study in esophageal/gej cancer
Published 7 years ago • 79 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:19
dr. kelly on the rationale for the checkmate-577 trial in esophageal/gej cancer
-
1:25
dr. chau on nivolumab in asian versus western patients with gastric/gej cancer
-
1:25
dr. chau on nivolumab in asian versus western patients with gastric/gej cancer
-
5:18
checkmate577: nivolumab in ec/gejc
-
13:47
checkmate 577 - is nivolumab adjuvant the standard of care in esophagus and gej?
-
7:38
treatment for recurrent gastroesophageal cancer
-
3:12
nivolumab for perioperative esophageal and gastroesophageal cancer: checkmate 577
-
4:14
adjuvant nivolumab in patients with resected esophageal or gej cancer (checkmate 577)
-
1:04:49
navigating multidisciplinary care with immunotherapy in esophageal/gej cancer
-
9:10
adjuvant nivolumab in resected oesophageal or goj cancer following chemo
-
4:29
advances in adjuvant and 1l immune checkpoint blockade for gastric and esophageal cancer
-
5:00
surgical advances in in gastric and gej cancer
-
4:49
emerging nivolumab strategies in gastric/gej cancers
-
8:16
nivolumab for oesophageal cancer following chemoradiation therapy
-
7:30
flot4: perioperative strategies in gastroesophageal cancer
-
3:47
nivolumab with or without ipilimumab in gastroesophageal junction cancer
-
2:19
jaffer ajani, md, shares thoughts on the checkmate 577 study presented at esmo 2020
-
1:25
dr. mehta on the evolution of treatment in gastric and gej cancers
-
5:06
treating unresectable or metastatic gastric/gej cancers